<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003495</url>
  </required_header>
  <id_info>
    <org_study_id>2013L01041</org_study_id>
    <secondary_id>2013L01041</secondary_id>
    <nct_id>NCT02003495</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine</brief_title>
  <official_title>Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine in Healthy Subjects 2 Months to 6 Years of Age in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Minhai Biotechnology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Minhai Biotechnology Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to evaluate the safety, reactogenicity and
      immunogenicity of Meninggococcal (A,C,Y and W135) Conjugate Vaccine in 2 months to 6
      years-old children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects exhibiting a &gt;= 4fold increase in rSBA titers level from pre-vaccination to post-vaccination</measure>
    <time_frame>28 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to evaluate the adverse reactions after vaccination</measure>
    <time_frame>Within 28 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2195</enrollment>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>MCV-ACYW135 Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.
Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.
Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.
Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPV-ACYW135 Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MPV-A Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCV-AC Vaccine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hib Vaccine Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCV-ACYW135 Vaccine Group</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>MCV-ACYW135 Vaccine Group</arm_group_label>
    <other_name>Meningococcal ( A, C, Y and W 135) conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MPV-ACYW135 Vaccine Group</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>MPV-ACYW135 Vaccine Group</arm_group_label>
    <other_name>Group A, C, Y and W-135 Meningococcal Polysaccharide Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MPV-A Vaccine Group</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>MPV-A Vaccine Group</arm_group_label>
    <other_name>Group A Meningococcal Polysaccharide vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCV-AC Vaccine Group</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>MCV-AC Vaccine Group</arm_group_label>
    <other_name>Group A and C Meningococcal conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hib Vaccine Group</intervention_name>
    <description>0.5ml, intramuscular</description>
    <arm_group_label>Hib Vaccine Group</arm_group_label>
    <other_name>Haemophilus Influenzae Type b Conjugate Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes will comply with the requirements of the
             protocol should be enrolled in the study.

          -  Healthy permanent residence 2 months to 6 years old.

          -  Subjects and parent/guardian able to attend all scheduled visits and comply with all
             study procedures.

          -  Axillary temperature ≤37.0 ℃.

        Exclusion Criteria:

          -  History of meningitis infection or vaccination of meningococcal vaccine within the
             past 6 months.

          -  Allergic history or any SAE after vaccination, such as allergy, urticaria, dyspnea,
             angioedema, celialgia.

          -  Patients administered with immunosuppressive agents, cytotoxicity factor or
             corticosteroids in the 6 months preceding the vaccine trial.

          -  Receipt of blood or blood-derived products in the 3 months preceding vaccination

          -  Participation in another clinical study investigating a vaccine, drug in the 30 days
             preceding vaccination.

          -  Receipt of any live virus vaccine in the 15 days preceding vaccination.

          -  Receipt of any subunit vaccine and inactivated vaccine in the 7 days before
             vaccination.

          -  Febrile illness (temperature ≥ 38°C) in the 3 days or any acute illness/infection in
             the 7 days preceding vaccination.

          -  Thrombocytopenia.

          -  History of thyroid gland excision or treatment for thyroid gland disease in last 12
             months.

          -  Functional or anatomic asplenia.

          -  History of eclampsia, epilepsy, encephalopathy and mental disease or family disease.

          -  Chronic disease (such as Down syndrome, diabetes, sickle cell anemia or neurologic
             disease, Guillain-Barre Syndrome).

          -  Known or suspected diseases, including: respiratory system disease, acute infection or
             active stage of chronic disease, HIV infection of children or mothers, cardiovascular
             disease, acute hypertension, cancer treatment, skin disease, etc.

          -  Any condition that, in the judgment of investigator, may affect trial assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shengli xia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henan Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>September 19, 2015</last_update_submitted>
  <last_update_submitted_qc>September 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity, Safety, Meningococcal Conjugate Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

